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We would like to thank Levi Sandri and colleagues for their com-
ments regarding our recently published article [1]. The authors
support our result that neither tumour thrombosis in a major
hepatic vein (mHVTT) nor portal vein tumour thrombosis, not
invading the main portal trunk, is a contraindication for liver
resection. In addition, they proposed further an aggressive
strategy for unresectable hepatocellular carcinoma (HCC), i.e.,
associating liver partition and portal vein ligation in a staged
hepatectomy (ALPPS) [2].
HCC with macroscopic vascular invasion is a challenging situ-
ation for surgical resection [3], and major hepatic resection is
often required [1,4,5]. Considering the progressive nature of the
disease, an urgent operation is also required. These situations
complicate the decision-making process, and many cases miss
their chance for a curative resection. Since ALPPS is reportedly
associated with a rapid hypertrophy of the remnant liver [2], this
technique may be a promising strategy for treating HCC with
macroscopic vascular invasion.
We have never attempted ALLPS in this setting. Instead, we
have proposed preoperative portal vein embolization (PVE) as a
possible strategy in cases with an insufﬁcient postoperative rem-
nant liver volume [6]. Actually, among 14 patients who under-
went a major hepatic resection for mHVTT, 4 patients (29%)
underwent preoperative PVE [1]. At present, PVE may be a stan-
dard strategy with an acceptable morbidity rate [7].
The presence of portal hypertension and impaired liver func-
tion (a 15 min indocyanine green retention rate of more than
20%) are contraindications for PVE [8]. These safety restrictions
should also be applied to ALPPS, since it is a more aggressive
strategy. As Levi Sandri et al. proposed, the Child-Pugh score
and the model for end-stage liver disease score may be useful
for making treatment-related decisions.
Data on this attractive approach are now being accumulated
through a worldwide registry system. However, the available
evidence remains insufﬁcient to support the use of ALPPS in cir-
rhotic patients with HCC [2,9]. Most of the evidence regarding
ALPPS is based on patients with colorectal liver metastases, in
whom the liver function has not been severely damaged. We
expect further reports on the role of the ALPPS procedure for
HCC patients requiring major hepatectomy.Chronic kidney disease after liver transplantation
To the Editor:
We read with interest the report by Allen et al. in a recent issue of
the Journal of Hepatology [1]. The authors are to be congratulated
on highlighting the important problem of chronic kidney disease
severe CKD (KDIGO stages 4–5) as in most previous literature,
their study additionally describes the incidence of lesser degrees
of renal injury (KDIGO stage 3) and has the beneﬁt of an iothala-
mate-measured glomerular ﬁltration rate (GFR). They found that(CKD) in liver transplant recipients. Instead of concentrating on few patients maintained ‘normal’ renal function long-term after
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applicable test for most transplant centres when repeated tests
are necessary. Although a useful research tool, a single absolute
measure of renal function in an individual patient is less relevant
than delta estimated GFR for modifying clinical care.
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majority of patients had stage 3 disease. However, echoing obser-
vations in the non-transplant setting, this moderate CKD (GFR
<60 ml/min/1.73 m2) was clinically relevant having implications
for survival [2,3].
There are several points worthy of comment. First, although
there was clearly a progressive deterioration in renal function
with time after transplant, the greatest loss occurred within the
ﬁrst year. The authors speculate that this reﬂects nephrotoxic
immunosuppressive drugs. Little mention was made of the role
of peri-operative acute kidney injury (AKI). In our unit, despite
optimized pre-transplant renal function and less calcineurin
inhibitor exposure in recent years, patients are experiencing more
GFR loss from baseline to 1-year [4]. This is in the context of a rise
in the incidence of AKI that has occurred in parallel with a marked
rise in the use of higher risk grafts [4]. We have hypothesized that
graft injury may play a critical role in the pathogenesis of AKI in
this setting. It is well recognized that AKI can cause permanent
structural damage, with progressive tubulo-interstitial ﬁbrosis
and long-term repercussions for renal function [5]. Therefore,
we suggest that in addition to renal sparing immunosuppression,
future strategies to prevent CKD may include therapies that
minimize the renal hit at time of transplantation.
Second, the apparent lack of era effect on the frequency of
CKD is interesting. United States registry data has shown that
the introduction of MELD has been accompanied by an increased
likelihood of end-stage kidney disease, which has been attributed
to greater pre-operative renal dysfunction [6]. Nevertheless,
given that the adjusted hazard ratio for renal failure only rose
by 15% after MELD implementation, one might not anticipate a
demonstrable difference in this comparatively small study. With-
out detailed information, regarding additional recipient and
donor factors, it is difﬁcult to draw any real conclusions regarding
the evolving incidence of CKD. Readers should not be falsely reas-
sured by this data, especially in the face of an escalating use of
higher risk grafts.
Finally, a major conclusion of the study by Allen et al. was the
limited reliability of creatinine-based GFR estimation in
predicting mortality in these patients, and that preventative
and expectant management, based on the early recognition of
renal dysfunction, may require actual measurement of GFR. We
argue that measured GFR is time-consuming, costly and not an
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To the Editor:
We appreciate the insightful comments of Leithead and Ferguson
regarding our recent analysis of prevalence of chronic kidney
disease (CKD) after liver transplantation (LT). We agree that
peri-operative acute kidney injury (AKI) contributes to the devel-
opment of chronic kidney disease after LT in a proportion of
patients. We did not ascertain the trajectory of renal function
in the early postoperative period in all our subjects. Since the ﬁrst
iothalamate clearance measurement was performed at 4 months
post-transplantation, we chose this interval as the ﬁrst point in
our time-dependent analysis. Our assumption that in the major-
ity of cases the renal dysfunction is attributed to calcineurin-
inhibitor nephrotoxicity was derived from the detailed chart
review of a small subset of patients with normal renal function
at the time of LT who developed CKD at 4 months. In this random
sample, only 27% of patients had postoperative AKI, deﬁned as
increase in creatinine by 0.3 mg/dl from baseline [1]. Thus, while
we acknowledge that postoperative AKI contributes to post-LT
CKD, we cannot quantify the degree to which it contributes to
CKD based on our data. We wholeheartedly agree that, given
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